Eurofins Optimed is a French Contract Research Organization (CRO) and Clinical Pharmacology Unit specialized in early‑phase clinical development. With more than 35 years of experience, the company supports pharmaceutical, biotechnology and medical device developers in the design, execution and management of Phase I and Phase II clinical trials in healthy volunteers and patients. Operating from its dedicated clinical facility in Gières, France, Eurofins Optimed combines scientific rigor, regulatory expertise and operational excellence to accelerate the transition from preclinical research to clinical proof of concept.

This established expertise now benefits from the French Fast Track regulatory framework, enabling accelerated timelines with authorization potentially granted within 14 days in eligible cases, further enhancing the attractiveness of France. Close interactions with sponsors, investigators and regulatory authorities further contribute to efficient study initiation and execution within this robust regulatory environment.

Eurofins Optimed provides a full‑service CRO offering, covering study design, regulatory submissions, clinical operations, volunteer and patient recruitment, pharmacovigilance, data management and biometry. The organization is particularly recognized for its expertise in First‑in‑Human studies, bioequivalence, drug–drug interaction studies, food‑effect studies and QT assessment, ensuring robust and high‑quality data generation in compliance with GCP and international regulatory standards.

A key differentiator of Eurofins Optimed is its strong integration within the Eurofins Group, enabling seamless collaboration with Eurofins ADME Bioanalyses and other specialized entities. This integrated model provides sponsors with end‑to‑end solutions combining clinical research, bioanalysis, pharmacokinetics and biomarker expertise, particularly valuable for complex and innovative drug development programs. Through this comprehensive and coordinated approach, Eurofins Optimed acts as a strategic partner for companies seeking to de‑risk and optimize early clinical development.

ETAP-LAB is an independent preclinical CRO that provides efficacy testing and pharmacology services to pharmaceutical, biotechnology and medtech companies.

ETAP-LAB has 35+ years of expertise with 4 services:
– BrainXplore: in vitro and in vivo models of Alzheimer, Parkinson, ALS, depression and anxiety.
– Stro@lliance: more than 10 models of both ischemic and hemorrhagic stroke.
– SkinAxis: inflammation models (psoriasis, atopic dermatitis,…) and wound healing (different shape, size, depth; skin grafting).
– SynCROsome: dedicated to Cardiology including HFpEF, HFrEF, Pulmonary Artery hypertension, Systemic hypertension, thrombosis.

ETAP-LAB’s services are designed to support drug discovery phases ranging from in vitro lead optimization to non-GLP animal testing (POC, PK/PD, non-regulatory safety pharmacology), to evaluate your drug candidates (small molecules, antibodies, cell therapies…) and medical devices.

ETAP LAB’s services rely on state of the art facilities and equipment, including high content imaging, in vivo imaging platforms (MRI, PET scan, echocardiography, dermoscopy), microsurgery capabilities, and comprehensive immunohistochemistry and bioassay readouts.

Neuron Experts is a private Contract Research Organization (CRO) established in 2008, specializing in neuronal culture systems modeling neurodegenerative diseases. The company has developed a range of proprietary assays based on human and rat in vitro models reproducing key pathological features of Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS), multiple system atrophy (MSA), multiple sclerosis (MS), and frontotemporal dementia (FTD). These models are used to evaluate compound efficacy and to investigate mechanisms of action.

Since 2025, Neuron Experts has collaborated with two French CROs—Motac, focused on in vivo studies, and Cynbiose, specialized in bioavailability and regulatory toxicology—within the INSPiRE consortium, with the objective of providing comprehensive preclinical development services for biotechnology companies.

In 2014, the company established a neurodermatology department dedicated to studying interactions between sensory neurons and the skin. It has developed human in vitro models to assess compound activity in dermatological and cosmetic applications. Notably, Neuron Experts has developed a reconstructed human epidermis model innervated with sensory neurons, enabling the evaluation of the effects of topically applied compounds on neuronal activity.

CYTOO transforms drug discovery through advanced micropatterned platforms that deliver highly physiological cell models, generating structural, functional, and metabolic readouts while enhancing AI-driven image analysis.

Within a portfolio of clinically relevant models, CYTOO’s flagship MyoScreen™ platform addresses inherited and acquired muscle disorders. Emerging models target obesity-related metabolic dysfunction, including myosteatosis and insulin resistance.

From high-throughput screening to GMP-grade potency assays, CYTOO has supported 60+ drug development programs, advancing therapies via standardized services, custom development, and strategic partnerships.

The company has a very strong expertise in neuro-muscular diseases, also other genetic disorders and metabolic disorders (muscle weakness and waste, obesity, diabetes).

The mission of CYTOO is to help advancing therapeutic candidates to the clinics leveraging its unique technology platform, from target identification, primary and secondary drug screening, up to the development of GMP-compliant potency assays for batch release.

Examples of targeted diseases:
Duchenne Muscular Dystrophy (DMD), Myotonic Dystrophy (DM1, DM2), Facioscapulohumeral Muscular Dystrophy (FSHD), Glycogen Storage Diseases (Pompe Disease), Mitochondrial Disorders (PMM – Primary Mitochondrial Myopathies), Metabolic Disorders (Sarcopenia, Diabetes, Obesity…)